—
C+
C+ The full Closelook — membership. Open the C+ overview

Travere Therapeutics Inc (TVTX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Travere Therapeutics Inc

TVTX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Travere Therapeutics develops and sells medicines for rare kidney and metabolic disorders. Its lead product, Filspari, treats IgA nephropathy by targeting two pathways involved in the disease's progression, and Thiola treats cystinuria, a genetic disorder causing kidney stones. It also runs early-stage programmes for related kidney and enzyme conditions. The company is based in San Diego and was previously named Retrophin.
Where it sits in the stack
Travere sits outside our AI build-out stack; it belongs to the healthcare and biotechnology sleeve of our universe rather than any Closelook index layer.
Who it is priced against
No peer group is assigned to Travere in our coverage; the market sometimes compares it with other rare-disease specialists such as Alnylam Pharmaceuticals.
Why Closelook tracks it
Travere holds no Closelook index seat and carries no Closelook score; the diary noted it once, in a Midday 10 quoting Barchart's large-cap new-high list where it appeared among the health-care and biotech names.
What the diary watches
Whether Filspari's use in kidney disease keeps widening and whether the clinical-stage programmes for other rare conditions progress toward approval.

Travere Therapeutics Inc (TVTX) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 44/100 composite (momentum 80, quality 27, valuation 9) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for TVTX, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against TVTX on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What TVTX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +13.1% in FY2025 45 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Travere Therapeutics Inc (TVTX)?

Travere Therapeutics Inc trades as TVTX on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is TVTX in a Closelook index?

Not currently — Travere Therapeutics Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is Travere Therapeutics Inc's Closelook composite score?

44 out of 100, with momentum 80, quality 27 and valuation 9 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does TVTX trade against its moving averages?

Pullback inside an uptrend stack: Trades -2.4% vs the 50-day and +36.9% vs the 200-day average, 12.3% below the 52-week high and +173.3% off the 52-week low. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Travere Therapeutics Inc do?

Travere Therapeutics develops and sells medicines for rare kidney and metabolic disorders. Its lead product, Filspari, treats IgA nephropathy by targeting two pathways involved in the disease's progression, and Thiola treats cystinuria, a genetic disorder causing kidney stones. It also runs early-stage programmes for related kidney and enzyme conditions. No peer group is assigned to Travere in our coverage; the market sometimes compares it with other rare-disease specialists such as Alnylam Pharmaceuticals.

Where does Travere Therapeutics Inc sit in the AI build-out?

Travere sits outside our AI build-out stack; it belongs to the healthcare and biotechnology sleeve of our universe rather than any Closelook index layer. Travere holds no Closelook index seat and carries no Closelook score; the diary noted it once, in a Midday 10 quoting Barchart's large-cap new-high list where it appeared among the health-care and biotech names.

Does Travere Therapeutics Inc pay a dividend?

No cash distribution shows in Travere Therapeutics Inc’s price series over the last three years. The share count rose 13.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

Where has Closelook written about Travere Therapeutics Inc?

Travere Therapeutics Inc appears in 1 Closelook piece, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelook said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for TVTX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelook

Where TVTX appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.